Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-γ and T Cells for Refractory Malignant Pleural Effusion
NCT05268172Phase 1Recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of interferon gamma-1b, unmodified CIK and CART-BCMA in malignant pleural effusion (MPE) and malignant ascites, sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Puncture-free Survival. Started Dec 2022; status: recruiting.
02
Drugs
interferon gamma-1bunmodified CIKCART-BCMA
03
Conditions
malignant pleural effusion (MPE)malignant ascites
Beyond the preview
Go deeper on NCT05268172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268172.